Biotechnology Corporate News

• Immunovaccine to Advance Biodefense Vaccines in a NIH Funded Study (Feb.14)
  
• BioTalent Canada Tool Offers Hope for Unemployed Manufacturing Workers in Kitchener Waterloo (Feb.8)
  
• John Helou named President of Pfizer Canada Inc. (Feb.8)
  
• Canadian Biotech Firms Look to Unemployed Manufacturing Workers to Fill Jobs (Feb.8)
  
• SemBioSys and Tasly Pharmaceutical to participate in the 5th Canada-China Business Forum and Signing Ceremony (Feb.8)
  
• Del Mar Pharmaceuticals to Present Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012 (Feb.7)
  
• Quebec is first in Canada to provide access to innovative treatment, XGEVA (Feb.7)
  
• OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences (Feb.7)
  
• First and only treatment to extend survival for people with metastatic melanoma, the most deadly form of skin cancer, approved in Canada (Feb.7)
  
• Sanofi Pasteur moves national immunization strategy forward with new bar code technology (Feb.7)
  
• OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences (Feb. 7)
  
• Del Mar Pharmaceuticals to Present Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012 (Feb. 7)
• COTI Identifies Phase 1 Oral Formulation Candidates for COTI-2 (Feb.2)
  
• Critical Outcome Technologies Inc. Identifies Phase 1 Oral Formulation Candidates for Coti-2 (Feb. 2)
  
• Del Mar Pharmaceuticals Granted U.S. Orphan Drug Designation for VAL-083 for the Treatment of Glioma (Feb. 2)
  
• PlantForm launches HIV antibody project (Jan.31)
  
• Cynapsus Therapeutics Announces Successful Human Volunteer Pilot Proof-of-Concept Results for APL-130277 (Jan.10)
• Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (Dec.28)
  
• Uncertain economic outlook limits growth in transportation, retail and food industries (Nov.24)
  
• CO2 Solutions Presents Update to Shareholders at its AGM (Nov.24)
• Resverlogix Announces $17.5 million Equity Offering (Nov.23)
• Pfizer Montreal manufacturing facility wins "Prix Innovation 2011" for cleaning process that increases efficiency and helps the environment (Nov.23)
  
• Ontario Government Shows Leadership in Oncology by Providing Access to Personalized Treatment (Nov.22)
• YM BioSciences Comments on Unusual Market Activity (Nov.22)
  
• Sirona Biochem's French subsidiary receives CDN $1.9-million grant for cosmeceutical project (Nov.22)
• Oncolytics Biotech® Inc. Announces Start of Conformity Testing with SAFC® (Nov.21)
• Treatment with XGEVA® (Denosumab) now one step closer for men with advanced prostate cancer with bone metastases (Nov.21)
• Resverlogix Commences Dosing in ASSURE a Phase 2b IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients (Nov.2)
• iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement (Nov.2)
  
• Philip Morris Investments B.V. exercises its pre-emptive right and invests an aggregate of $22.5 million in Medicago through a two tranche Private Placement (Oct.27) 
  
• Bioniche Life Sciences Inc. Receives Canadian Regulatory Approval for Equine Anti-Inflammatory Product (Oct.27)
  
• Health Canada Clears Immunovaccine for Ovarian Cancer Vaccine Trials (Oct.26)